Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04881942
Other study ID # ALCS-RA-17-06-EV
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 27, 2017
Est. completion date January 26, 2018

Study information

Verified date March 2021
Source Altria Client Services LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, 4-way crossover study designed to estimate the nicotine, glycerin, propylene glycol, menthol, formaldehyde, acetaldehyde, and acrolein levels in exhaled breath samples during use of four MarkTen® XL e-vapor products. The study will enroll approximately 32 adult e-vapor-using subjects at one site in the United States in High Point, NC.


Description:

This is an open-label, 4-way crossover study designed to estimate the nicotine, glycerin, propylene glycol, menthol, formaldehyde, acetaldehyde, and acrolein levels in exhaled breath samples during use of four MarkTen® XL e-vapor products (which are no longer manufactured or sold commercially). The study will enroll approximately 32 adult e-vapor-using (with no more that 60% of either sex). Each of the 32 subjects will provide two exhaled breath samples (10 puffs for each sample) for all four test products. Subjects will make two visits to the site, one screening visit and one 4 day in-clinic visit to provide exhalation samples for four test products (one each day for 4 days). Subjects will also use their assigned test product ad libitum for 12 hours each day after the collection of exhaled breath samples. Subjects will be randomly assigned to a test product-use schedule at Visit 2, with one test product used per day. The anticipated study duration for each subject from screening through completion of all study participation will be approximately 34 days.


Recruitment information / eligibility

Status Completed
Enrollment 35
Est. completion date January 26, 2018
Est. primary completion date April 21, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 65 Years
Eligibility Inclusion Criteria: - Subject candidates must satisfy the following criteria before being enrolled in the study: 1. provide voluntary consent to participate, as documented by the signed institutional review board (IRB)-approved informed consent form (ICF) for the study; 2. be between the ages of 21 and 65 years, inclusive, at the time of screening (Visit 1); 3. be positive for tobacco use by urine cotinine measurement (= 500 ng/mL) at Visit 1 (screening); 4. have used nicotine-containing EVPs for the 3 months before Visit 1 (screening) and use of nicotine-containing EVPs ("some days" or "every day") for the past 30 days and at least 4 out of the past 7 days before Visit 1 (screening) and at check-in for Visit 2; 5. have negative alcohol, amphetamines, opiates, cannabinoids, phencyclidine, and cocaine urine drug screening results (exhaled breath test for alcohol is also acceptable) at Visit 1 (screening) and at check-in for Visit 2; 6. if female (all females), have a negative serum pregnancy test at Visit 1 (screening) and have a negative urine pregnancy test at check-in for Visit 2; 7. if female and heterosexually active and of childbearing potential (e.g., not surgically sterile [i.e., bilateral tubal ligation, hysterectomy, or bilateral oophorectomy] at least 6 months before Visit 1 [screening] or at least 2 years naturally postmenopausal [follicle-stimulating hormone =40 IU/L at Visit 1 (screening)]), must be using one of the following forms of contraception and agree to continue using it through at least 30 days after the last study product use (if early terminated) or completion of the study: - hormonal (e.g., oral, transdermal patch, implant, or injection) consistently for at least 3 months before Visit 1 (screening); - double barrier (i.e., condom with spermicide or diaphragm with spermicide) consistently for at least 30 days before Visit 1 (screening); - intrauterine device for at least 3 months before Visit 1 (screening); - Essure® or similar nonsurgical sterilization procedure at least 3 months before Visit 1 (screening); or - partner who has been vasectomized for at least 6 months (inclusive) before Visit 1 (screening); 8. if male and heterosexually active and capable of fathering a child (e.g., not vasectomized at least 6 months before Visit 1 [screening]), must be using a double barrier (i.e., condom with spermicide or diaphragm with spermicide) method of contraception from check-in at Visit 2 until at least 90 days after the last study product use (if early terminated) or completion of the study; 9. not plan to quit e-vapor use in the next 30 days; 10. be willing to use all assigned EVPs during the study; and 11. be willing and able to comply with the requirements of the study. Exclusion Criteria: - Subjects may be excluded from the study if the subject meets any of the criteria listed below at Visit 1 (screening) and Visit 2 or at any time during the study as appropriate. Exceptions may be permitted at the discretion of the investigator in consultation with the Sponsor, providing there would be no additional risk involved for the subject. Any exceptions will be documented. 1. have a history or presence of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, urologic, diabetes, existing respiratory diseases (especially bronchospastic diseases and asthma), immunologic, psychiatric, cardiovascular disease, or any other condition(s) that, in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results (Note: Chronic medical conditions controlled and on stable medications [over the past 3 months] may not be exclusionary per investigator discretion); 2. have current evidence or any history of congestive heart failure; 3. have clinically significant abnormal findings on physical examination, vital signs, ECG, clinical laboratory results, or medical history, in the opinion of the investigator; 4. have systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg at Visit 1 (screening) or at check-in for Visit 2; 5. have estimated creatinine clearance (by Cockcroft-Gault equation) <80 mL/minute; 6. have liver enzymes (aspartate aminotransferase and alanine aminotransferase) =1.5 times the upper limit of normal at Visit 1 (screening); 7. have an acute illness (e.g., upper respiratory infection or viral infection) requiring treatment within 2 weeks before check-in at Visit 2; 8. have fever (>100.5°F) at Visit 1 (screening) or at check-in for Visit 2; 9. have body mass index (BMI) greater than 40.0 kg/m2 or less than 18.0 kg/m2 at Visit 1 (screening); 10. have positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) at Visit 1 (screening); 11. have used prescription or over-the-counter bronchodilator medication (e.g., inhaled or oral ß-agonists) within 12 months of Visit 1 (screening) and Visit 2; 12. have diabetes mellitus that is not controlled by diet/exercise alone, in the opinion of the investigator; 13. have used prescription antidiabetic medication or insulin therapy within 12 months of Visit 1 (screening) and Visit 2; 14. have used medication for depression or asthma within 12 months of Visit 1 (screening) and Visit 2; 15. have a history of drug or alcohol abuse within 12 months of Visit 1 (screening) and Visit 2; 16. have had allergic or other known adverse reactions to menthol, propylene glycol, or glycerol; 17. if female, be pregnant, nursing, or planning to become pregnant during the study; 18. have participated in a clinical study for an investigational drug, medical device, biologic, or for a tobacco product within 30 days before Visit 1 (screening) and Visit 2; 19. be a current or former employee of the tobacco industry or a first-degree relative (e.g., parent, spouse, sibling, child) of a current or former employee of the tobacco industry or a named party or class representative in litigation with any tobacco company; 20. have been involved in the development of the study design/conduct or be a first-degree relative (e.g., parent, spouse, sibling, child) of someone involved in the development of the study design/conduct; 21. be a current employee or personnel involved with the study at the site; or 22. have participated in two or more ALCS studies within the past 12-month period before Visit 1 (screening) and check in at Visit 2.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
e-Vapor Product A
e-Vapor product
e-Vapor Product B
e-Vapor product
e-Vapor Product C
e-Vapor product
e-Vapor Product D
e-Vapor product

Locations

Country Name City State
United States High Point Clinical Trials Center High Point North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Altria Client Services LLC Cato Research

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Nicotine ug (micrograms) in exhaled breath samples collected during each product use session 4 Days (Day 1 through Day 4)
Primary Glycerin ug (micrograms) in exhaled breath samples collected during each product use session 4 Days (Day 1 through Day 4)
Primary Propylene Glycol ug (micrograms) in exhaled breath samples collected during each product use session 4 Days (Day 1 through Day 4)
Primary Menthol ug (micrograms) in exhaled breath samples collected during each product use session 4 Days (Day 1 through Day 4)
Primary Formaldehyde ug (micrograms) in exhaled breath samples collected during each product use session 4 Days (Day 1 through Day 4)
Primary Acetaldehyde ug (micrograms) in exhaled breath samples collected during each product use session 4 Days (Day 1 through Day 4)
Primary Acrolein ug (micrograms) in exhaled breath samples collected during each product use session 4 Days (Day 1 through Day 4)
Secondary Cartridge Weight mg (milligrams) collected before and after each product use 4 Days (Day 1 through Day 4)
Secondary Puff count Number of puffs taken during 12-hour ad libitum product use session 4 Days (Day 1 through Day 4)
Secondary Puff Duration Seconds per puff taken during 12-hour ad libitum product use session 4 Days (Day 1 through Day 4)
Secondary Use Product Again Questionnaire Visual Analog Scale (VAS) measuring self-reported response to willingness to use study product again questionnaire collected after each product use session. Questionnaire consists of a single question ("If given the opportunity, I would want to use this product again") with VAS response range from "Definitely Would Not" to "Don't Care" to "Definitely Would" 4 Days (Day 1 through Day 4)
See also
  Status Clinical Trial Phase
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Recruiting NCT06033599 - Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement Phase 3
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT06105424 - BRP1602: Evaluation of Technical and Logistical Feasibility to Measure Lung Permeability N/A
Completed NCT01311830 - Enhancing Smoker Utilization of the Minnesota Quitline Through Support Persons N/A
Completed NCT04566198 - Smoking in the Paris Fire Brigade and Comparison According to the Type of Service (Permanent or On-call)
Completed NCT04107779 - Changes in Biomarkers of Cigarette Smoke Exposure After Switching Either Exclusively or Partly to JUUL ENDS N/A
Completed NCT05092919 - The Effect of Sweet Flavoring on the Rewarding and Reinforcing Value of Cigarillo Use Among Young Adults Early Phase 1
Terminated NCT05274217 - Journey of Transformation Curriculum for Native American Adolescents N/A
Enrolling by invitation NCT06042361 - Enhancing Equity in Smoke-free Housing N/A
Withdrawn NCT03352635 - Mechanisms of Ethnic/Racial Differences in Lung Cancer Due to Cigarette Smoking Clinical and Biomarkers Core N/A
Completed NCT03235713 - EMA for Tobacco Control Policy Research
Completed NCT03151421 - Air Quality Feedback to Reduce Second-hand Smoke (SHS) Exposure in the Home N/A
Completed NCT03446170 - Effect of Cigarette Pack Warnings and Packaging Among Young Adult Smokers N/A
Completed NCT04104152 - CSD190203: A Study to Determine Subject Puffing Patterns of an Electronic Nicotine Delivery System in an Ambulatory Setting N/A
Not yet recruiting NCT05999383 - Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration Phase 2
Recruiting NCT04429568 - THC Crossover Study N/A
Completed NCT04632030 - Shrinking the Size of the Tobacco Power Wall N/A
Completed NCT04094363 - CSD190202: Study to Assess Elements of Abuse Liability for Two Electronic Nicotine Delivery Systems N/A